9 papers in the library · 77 citations · publishing 2023-2026
JAMA Network Open September 29, 2026 Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara N Lappan, Richard C. Shelton et al. 4 citations
Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a...
International Journal of Mental Health and Addiction March 17, 2026 Haley Maria Dourron, Melissa Bradley, Heith Copes et al.
Abstract Despite a long-standing interest in the potential similarities between psychedelic and psychotic experiences, no recent research has systematically explored the subjective overlap between these states in individuals who have experienced both. To provide rich accounts of potential overlaps and distinctions, we conducted semi-structured interviews with 19 individuals diagnosed with...
Frontiers in Psychiatry December 9, 2025 Haley Maria Dourron, Heith Copes, Daniel H. Grossman et al. 3 citations
Background: People with a history of psychotic disorders are excluded from contemporary trials of psychedelic-assisted therapy. Although survey studies have explored the impact of naturalistic psychedelic use on people with a history of psychotic disorders, a qualitative study has yet to examine the subjective effects of psychedelic use in this population during both the acute effects and...
Psychedelic Medicine June 1, 2025 Haley Maria Dourron, Melissa Bradley, Otto Simonsson et al. 7 citations
Prior research examining the associations between psychedelic use and general psychotic symptoms has yielded mixed findings. However, no studies have investigated the relationships between psychedelic use and specific psychotic symptoms, and whether these relationships might differ among those with liability to psychosis, namely those with a history of psychotic or bipolar disorders. Using...
The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2025 Melissa Bradley, Daniel H. Grossman, Otto Simonsson et al. 1 citation
Recent legislative initiatives in the United States have focused on the medical and legal status of psychedelics, prompting interest in understanding public perceptions of their risks. This study investigates rural-urban differences in the perception of LSD and cannabis risks using national survey data. Data from the National Survey of Drug Use and Health (NSDUH) between 2015 and 2021 were...
November 22, 2024 Haley Maria Dourron, Melissa Bradley, Peter S. Hendricks 1 citation preprint
Myran et al. report that emergency room (ER) visits involving hallucinogens are associated with a 21.32 greater risk of being diagnosed with a schizophrenia spectrum disorder (SSD).1 Although implications for the development of psychedelics as medicines are discussed, we highlight some important distinctions.
Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations
5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...
The Journal of Clinical Psychiatry May 4, 2023 Sandeep M. Nayak, Melissa Bradley, Bethea A Kleykamp et al. 38 citations
To systematically review control conditions of all available randomized psychedelic trials. We searched PubMed, PsycINFO, and EMBASE for randomized trials of psychedelics in humans from 1940 through May 2020 with no language restrictions. PRISMA guidelines were followed. (PROSPERO registration number: PROSPERO-CRD42020205341.). All randomized trials of psychedelics in humans from 1940 through...